Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Viracta Therapeutics, Inc.
  6. News
  7. Summary
    VIRX   US92765F1084

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) added to NASDAQ Biotechnology Index

12/20/2021 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

Viracta Therapeutics, Inc. has been added to NASDAQ Biotechnology Index.


© S&P Capital IQ 2021
All news about VIRACTA THERAPEUTICS, INC.
05/13Viracta Therapeutics Announces New Employment Inducement Grant
PR
05/11Viracta Therapeutics to Present at Upcoming May Investor Conferences
PR
05/10SUNESIS : Q1 Earnings Snapshot
AQ
05/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
PR
04/27VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27TRANSCRIPT : Viracta Therapeutics, Inc. - Special Call
CI
04/20Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment o..
PR
04/15VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/15Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election A..
CI
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -47,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,77x
Yield 2022 -
Capitalization 77,6 M 77,6 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 28
Free-Float 60,7%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,07 $
Average target price 20,00 $
Spread / Average Target 866%
EPS Revisions
Managers and Directors
Ivor Royston Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Director
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-43.29%76
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524